Rediscovering GIP – the overlooked hormone in type 2 diabetes mellitus

shutterstock_1051189754 - image for home page-01

Innovative approaches to safe, effective glucose and weight control in T2DM: how once-weekly tirzepatide targets both GIP and GLP-1 receptors, complementary actions mediate the prandial/postprandial incretin effect

Learning objectives

You will learn:

  • The current understanding of the pathophysiology of type 2 diabetes mellitus (T2DM)
  • The role of the incretin effect in the pathophysiology of T2DM and how GIP and GLP-1 mediate this effect
  • The role of the gut-pancreas axis in incretin signalling
  • Clinical evidence supporting the efficacy of tirzepatide, a new-generation incretin therapy for
    the control of glycaemia and weight in T2DM.
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don't upload these yourself.

To access this module, please register or login: